Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was $1.76 for the day, up 0.57% from the previous closing price of $1.75. In other words, the price has increased by $0.57 from its previous closing price. On the day, 0.65 million shares were traded. VRCA stock price reached its highest trading level at $1.82 during the session, while it also had its lowest trading level at $1.7.
Ratios:
Our analysis of VRCA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.23 and its Current Ratio is at 2.36.
On March 22, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $10.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on February 13, 2023, whereas the target price for the stock was revised from $4 to $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 26 ’24 when Hayes Christopher G. sold 26,183 shares for $2.66 per share. The transaction valued at 69,647 led to the insider holds 115,303 shares of the business.
Hayes Christopher G. sold 9,530 shares of VRCA for $23,444 on Aug 27 ’24. The CHIEF LEGAL OFFICER now owns 105,773 shares after completing the transaction at $2.46 per share. On Aug 26 ’24, another insider, Goldenberg Gary, who serves as the Chief Medical Officer of the company, sold 9,888 shares for $2.66 each. As a result, the insider received 26,302 and left with 97,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRCA now has a Market Capitalization of 75096736 and an Enterprise Value of 89049968. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.40. Its current Enterprise Value per Revenue stands at 6.403 whereas that against EBITDA is -1.149.
Stock Price History:
Over the past 52 weeks, VRCA has reached a high of $11.41, while it has fallen to a 52-week low of $1.75. The 50-Day Moving Average of the stock is -57.91%, while the 200-Day Moving Average is calculated to be -70.46%.
Shares Statistics:
VRCA traded an average of 686.01K shares per day over the past three months and 464200 shares per day over the past ten days. A total of 42.41M shares are outstanding, with a floating share count of 26.07M. Insiders hold about 38.89% of the company’s shares, while institutions hold 43.77% stake in the company. Shares short for VRCA as of 1724976000 were 2981724 with a Short Ratio of 4.35, compared to 1722384000 on 3686949. Therefore, it implies a Short% of Shares Outstanding of 2981724 and a Short% of Float of 15.689998999999998.
